Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals. However, vaccines being developed for use in animals have the potential to be developed for use in humans. This study was aimed to design and analysis of multi epitope vaccine against Clostridium perfringens type A and E.
Material-Method: The B cell epitopes were predicted by IEDB and MHC II epitopes were predicted by Vaxign web server.
Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa. The half-life of candidate vaccine was found to be greater than 100 hours in mammalian cells, greater than 20 hours in yeast, and greater than 10 hours in Escherichia coli. The instability index of vaccine was 28.41 (<40), the aliphatic index was found to be 47.51, and the vaccine is soluble in water and is considered stable. The grand average of hydropathicity of candidate vaccine is -1.283, consequently, the vaccine is a hydrophilic protein and easily soluble in water. The result obtained from of Toxinpred and Allertop revealed that the protein don’t have tixic and allergenic effect on human and animal cells. Pepcalc and Protparam analysis showed that the vaccine doesn’t have transmembrane helix in its structure, so no expression difficulties are expected in the development of the protein from recombinant dNa technology methods. The result obtained from docking analysis proved that the vaccine has maximum affinity to HLA-DRB1*0101 with the score of -660.73.
Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.
Objective: Clostridium perfringens is a spore-forming, anaerobic, gram positive, bacteria that exist in environment, soils, foods, and in intestinal traces of humans or animals. However, vaccines being developed for use in animals have the potential to be developed for use in humans. This study was aimed to design and analysis of multi epitope vaccine against Clostridium perfringens type A and E.
Material-Method: The B cell epitopes were predicted by IEDB and MHC II epitopes were predicted by Vaxign web server.
Results: Physicochemical study of vaccine showed that the designed vaccine is 58.33 kDa. The half-life of candidate vaccine was found to be greater than 100 hours in mammalian cells, greater than 20 hours in yeast, and greater than 10 hours in Escherichia coli. The instability index of vaccine was 28.41 (<40), the aliphatic index was found to be 47.51, and the vaccine is soluble in water and is considered stable. The grand average of hydropathicity of candidate vaccine is -1.283, consequently, the vaccine is a hydrophilic protein and easily soluble in water. The result obtained from of Toxinpred and Allertop revealed that the protein don’t have tixic and allergenic effect on human and animal cells. Pepcalc and Protparam analysis showed that the vaccine doesn’t have transmembrane helix in its structure, so no expression difficulties are expected in the development of the protein from recombinant dNa technology methods. The result obtained from docking analysis proved that the vaccine has maximum affinity to HLA-DRB1*0101 with the score of -660.73.
Conclusion: The result of this study showed that the candidate vaccine can be stimulate HLA-DRB1*0101 and other MCHII alleles.
B cell Clostridium perfringens HLA-DRB1*0101 Type E Type A Vaccine
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Araştırma Makaleleri |
Yazarlar | |
Yayımlanma Tarihi | 15 Haziran 2020 |
Gönderilme Tarihi | 28 Ocak 2020 |
Yayımlandığı Sayı | Yıl 2020 Cilt: 11 Sayı: 2 |
SDÜ Sağlık Bilimleri Dergisi, makalenin gönderilmesi ve yayınlanması dahil olmak üzere hiçbir aşamada herhangi bir ücret talep etmemektedir. Dergimiz, bilimsel araştırmaları okuyucuya ücretsiz sunmanın bilginin küresel paylaşımını artıracağı ilkesini benimseyerek, içeriğine anında açık erişim sağlamaktadır.